Dexamethasone Sodium Phosphate
NDC Package 50090-0627-1

11-digit billing NDC: 50090062701

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Dexamethasone Sodium Phosphate is intravenous or Intramuscular InjectionWhen oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:• Endocrine Disorders     Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)     Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)     Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful     Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected     Congenital adrenal hyperplasia     Nonsuppurative thyroiditis     Hypercalcemia associated with cancer• Rheumatic Disorders     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     Post-traumatic osteoarthritis     Synovitis of osteoarthritis     Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)     Acute and subacute bursitis      Epicondylitis     Acute nonspecific tenosynovitis     Acute gouty arthritis     Psoriatic arthritis     Ankylosing spondylitis• Collagen Diseases     During an exacerbation or as maintenance therapy in selected cases of:     Systemic lupus erythematosus     Acute rheumatic carditis• Dermatologic Diseases     Pemphigus     Severe erythema multiforme (Stevens-Johnson syndrome)     Exfoliative dermatitis     Bullous dermatitis herpetiformis     Severe seborrheic dermatitis     Severe psoriasis     Mycosis fungoides• Allergic States     Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:     Bronchial asthma     Contact dermatitis     Atopic dermatitis     Serum sickness     Seasonal or perennial allergic rhinitis     Drug hypersensitivity reactions     Urticarial transfusion reactions     Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)• Ophthalmic Diseases     Severe acute and chronic allergic and inflammatory processes involving the eye, such as:     Herpes zoster ophthalmicus     Iritis, iridocyclitis     Chorioretinitis     Diffuse posterior uveitis and choroiditis     Optic neuritis     Sympathetic ophthalmia     Anterior segment inflammation     Allergic conjunctivitis     Keratitis     Allergic corneal marginal ulcers• Gastrointestinal Diseases     To tide the patient over a critical period of the disease in:     Ulcerative colitis (Systemic therapy)     Regional enteritis (Systemic therapy)• Respiratory Diseases     Symptomatic sarcoidosis     Berylliosis     Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means     Aspiration pneumonitis• Hematologic Disorders     Acquired (autoimmune) hemolytic anemia      Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)     Secondary thrombocytopenia in adults     Erythroblastopenia (RBC anemia)     Congenital (erythroid) hypoplastic anemia• Neoplastic Diseases     For palliative management of:     Leukemias and lymphomas in adults     Acute leukemia of childhood• Edematous States     To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus• Miscellaneous     Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy     Trichinosis with neurologic or myocardial involvement• Diagnostic testing of adrenocortical hyperfunction• Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury.     Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. Marketed by A-s Medication Solutions, this product is identified by NDC 50090-0627 and is authorized under FDA application ANDA084916.

Identification & Billing

NDC Package Code
50090-0627-1
Package Description
1 VIAL, MULTI-DOSE in 1 CONTAINER / 5 mL in 1 VIAL, MULTI-DOSE
Product Code
11-Digit Billing Format
50090062701
RxNorm Crosswalk
  • RxCUI: 1116927 - dexAMETHasone sodium phosphate 4 MG/ML (dexAMETHasone phosphate equivalent) Injectable Solution
  • RxCUI: 1116927 - dexamethasone phosphate 4 MG/ML Injectable Solution
  • RxCUI: 1116927 - dexamethasone phosphate 4 MG/ML (as dexamethasone sodium phosphate 4.4 MG/ML) Injectable Solution

Clinical Specifications

Proprietary Name
Dexamethasone Sodium Phosphate
Dosage Form
-
Usage Information
Intravenous or Intramuscular InjectionWhen oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:• Endocrine Disorders     Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance)     Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used)     Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful     Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected     Congenital adrenal hyperplasia     Nonsuppurative thyroiditis     Hypercalcemia associated with cancer• Rheumatic Disorders     As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:     Post-traumatic osteoarthritis     Synovitis of osteoarthritis     Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)     Acute and subacute bursitis      Epicondylitis     Acute nonspecific tenosynovitis     Acute gouty arthritis     Psoriatic arthritis     Ankylosing spondylitis• Collagen Diseases     During an exacerbation or as maintenance therapy in selected cases of:     Systemic lupus erythematosus     Acute rheumatic carditis• Dermatologic Diseases     Pemphigus     Severe erythema multiforme (Stevens-Johnson syndrome)     Exfoliative dermatitis     Bullous dermatitis herpetiformis     Severe seborrheic dermatitis     Severe psoriasis     Mycosis fungoides• Allergic States     Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:     Bronchial asthma     Contact dermatitis     Atopic dermatitis     Serum sickness     Seasonal or perennial allergic rhinitis     Drug hypersensitivity reactions     Urticarial transfusion reactions     Acute noninfectious laryngeal edema (epinephrine is the drug of first choice)• Ophthalmic Diseases     Severe acute and chronic allergic and inflammatory processes involving the eye, such as:     Herpes zoster ophthalmicus     Iritis, iridocyclitis     Chorioretinitis     Diffuse posterior uveitis and choroiditis     Optic neuritis     Sympathetic ophthalmia     Anterior segment inflammation     Allergic conjunctivitis     Keratitis     Allergic corneal marginal ulcers• Gastrointestinal Diseases     To tide the patient over a critical period of the disease in:     Ulcerative colitis (Systemic therapy)     Regional enteritis (Systemic therapy)• Respiratory Diseases     Symptomatic sarcoidosis     Berylliosis     Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means     Aspiration pneumonitis• Hematologic Disorders     Acquired (autoimmune) hemolytic anemia      Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated)     Secondary thrombocytopenia in adults     Erythroblastopenia (RBC anemia)     Congenital (erythroid) hypoplastic anemia• Neoplastic Diseases     For palliative management of:     Leukemias and lymphomas in adults     Acute leukemia of childhood• Edematous States     To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus• Miscellaneous     Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy     Trichinosis with neurologic or myocardial involvement• Diagnostic testing of adrenocortical hyperfunction• Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury.     Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.

Regulatory & Marketing

Labeler Name
A-s Medication Solutions
FDA Application #
ANDA084916
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-07-2000
Listing Expiration
12-31-2022
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (50090-0627). Click a package code to view its specific billing and regulatory data.

2 VIAL, MULTI-DOSE in 1 CONTAINER / 5 mL in 1 VIAL, MULTI-DOSE
25 VIAL, MULTI-DOSE in 1 TRAY / 5 mL in 1 VIAL, MULTI-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 50090-0627-1 identifies a specific commercial package of 1 vial, multi-dose in 1 container / 5 ml in 1 vial, multi-dose of Dexamethasone Sodium Phosphate, labeled by A-s Medication Solutions. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by A-s Medication Solutions on September 07, 2000. The current certification is valid through December 31, 2022.

How is this A-s Medication Solutions product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 50090062701. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
50090-0627-1
11-Digit CMS (5-4-2)
50090-0627-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.